The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Objectives
To evaluate and compare the efficacy of sequential treatment with abiraterone followed by enzalutamide or vice versa for castration‐resistant prostate cancer.
Methods
We retrospectively evaluated data on 198 consecutive chemotherapy‐naïve patients who had received both abiraterone and enzalutamide for castration‐resistant prostate cancer at Kyoto University Hospital (including satellite...
BACKGROUNDMicroRNAs are noncoding small RNA that negatively regulate target gene expression by binding to the 3′‐UTR of mRNA. Previous studies have shown that several microRNAs play a pivotal role in prostate cancer by acting as oncogenes or tumor suppressors. This study was aimed at identifying microRNAs that contribute to the progression to castration resistant prostate cancer.
METHODSMicroRNAs...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.